After a stroke, clinicians and patients struggle to determine if and
when muscle activity and movement will return. Surface electromyography
(EMG) provides a non-invasive window into the nervous system that can be
used to monitor muscle activity, but is rarely used in acute care. In
this perspective paper, we share our experiences deploying EMG in the
clinic to monitor stroke survivors. Our experiences have demonstrated
that deploying EMG in acute care is both feasible and useful. We found
that current technology can be used to comfortably and non-obtrusively
monitor muscle activity, even for patients with no detectable muscle
activity by traditional clinical assessments. Monitoring with EMG may
help clinicians quantify muscle activity, track recovery, and inform
rehabilitation. With further research, we perceive opportunities in
using EMG to inform prognosis, enable biofeedback training, and provide
metrics necessary for supporting and justifying care. To leverage these
opportunities, we have identified important technical challenges and
clinical barriers that need to be addressed. Affordable wireless EMG
system that can provide high-quality data with comfortable, secure
interfaces that can be worn for extended periods are needed. Data from
these systems need to be quickly and automatically processed to create
round-ready results that can be easily interpreted and used by the
clinical team. We believe these challenges can be addressed by
integrating and improving current methods and technology. Deploying EMG
in the clinic can open new pathways to understanding and improving
muscle activity and recovery for individuals with neurologic injury in
acute care and beyond.
Introduction
Every brain injury is unique—making individualized
evaluations especially important for diagnosis and prognosis. For
individuals who have had a stroke, impaired movement is one of the most
persistent and disabling sequela, severely limiting participation, and
quality of life (1–3).
Many individuals initially have limited or no ability to move their
limbs after stroke. However, determining when and if an individual will
regain movement is challenging (4–6).
Surface electromyography (EMG) provides a non-invasive window to
observe neuromotor activity. By monitoring activity and observing
resulting movements, we can evaluate the integrity of neuromotor
pathways (7). The initial weeks after stroke are viewed as a critical period of neural plasticity and recovery (8), yet EMG is rarely deployed during this time.
In acute care, function-based clinical exams remain the
standard for evaluating and monitoring muscle activity and movement. The
Manual Muscle Test (MMT) and NIH Stroke Scale (NIHSS) are among the
most common evaluation measures used in the United States. These
measures are often performed daily in the hospital to track recovery and
document outcomes for insurance purposes. Clinicians conduct these
measures by asking individuals to attempt to voluntarily move specific
body parts, assigning an ordinal score based upon observed movement or
muscle activity felt by palpation (9–12).
Members of the care team can conduct these exams quickly, but they are
coarse measures that provide limited insight into the extent of injury
or prognosis, especially for individuals with language barriers,
receptive aphasia, neglect, or other impairments that limit ability to
follow instructions. The Fugl-Meyer Assessment (FMA) expands the
repertoire of movements to evaluate synergistic or other inappropriate
muscle activity (13, 14). While the FMA has shown promise for predicting recovery and future function (15),
it is not often used in the clinic due to the time and training
required. Like the MMT and NIH Stroke Scale, it also has limited utility
for individuals with impaired voluntary movement or difficulty
following instructions. An ideal assessment tool to monitor muscle
activity and movement after stroke would provide deeper insight into the
quantity and quality of movement, while requiring minimal time to
execute.
In the 1950s, clinicians like Thomas Twitchell deployed EMG to monitor muscle activity (16–19),
but today EMG is mainly confined to research settings. Twitchell's
detailed observations of EMG recordings from stroke survivors in acute
care remain some of our most detailed descriptions of early muscle
activity after stroke. Twitchell would not recognize today's
sophisticated EMG systems (20).
Large sensors and tangles of wires have been replaced by sleek, small
packages that wirelessly transmit data from dry electrodes that make it
easier to target and isolate activity from individual muscles. Material
selection and electrode design continue to improve, such that EMG
sensors can even be worn for multiple days with minimal impact on signal
quality or skin health (21–23).
One of the largest changes has come in our processing and analytic
ability. We have replaced the chart recorders that Twitchell used with
systems that easily capture and analyze recordings (24, 25).
EMG sensors can also be integrated with other sensors, such as inertial
measurement units (IMUs) that provide concurrent measurements of
movement.
Despite all of the opportunities provided by this
advancement, the translation of EMG to clinical care has been a slow
process. In this paper, we share our team's perspective translating EMG
into the clinic through a multidisciplinary collaboration between
engineers and clinicians. Over the past two years, we have monitored
muscle activity with adult stroke survivors within the first 5 days
after stroke. This experience has shown our team that there are great
opportunities in expanding the use of EMG in clinical care, but
significant barriers that need to be overcome to facilitate this
translation. We hope our experiences and lessons learned can support
other teams attempting this translation and accelerate the use of EMG
technology to advance care.
Surface EMG In Acute Care
“I think my finger moved today” is a phrase that many
clinicians in acute stroke care or rehabilitation have heard from a
stroke survivor. During the early weeks, movement can return rapidly and
seemingly unexpectedly, which makes every twitch or sensation a
potential positive sign (19).
Clinicians and their patients often cannot definitively determine
whether an individual voluntarily moved their arm or finger, or if there
were changes compared to yesterday (26, 27).
While a clinician cannot wait by the bedside, an EMG system can
unobtrusively monitor muscle activity while the patient and clinical
team continue with standard care. Of course, the acute setting presents
unique challenges in deploying any technology (28).
Large care teams work around the clock to coordinate and conduct
numerous tests and procedures to address the initial injury and prevent
further damage.
In our work to deploy EMG in this challenging
environment, our team prioritized selecting an EMG system that provided
wireless sensing in a compact form. The BioStampRC sensors (BioStampRC,
MC10, Lexington, MA) included integrated EMG and accelerometer sensors
that could concurrently monitor muscle activity and movement. We
targeted the muscles most commonly assessed by the clinical team,
placing sensors on five muscle groups: the deltoid, biceps, triceps,
wrist flexors, and wrist extensors of the affected upper extremity (Figure 1).
We followed SENIAM guidelines for placing the sensors, but often had to
adjust to accommodate IV's, bandages, or telemetry pads. Loose skin,
adipose tissue, and sweat were also common issues that impacted signal
quality and sensor adherence.
We deployed these sensors with
stroke survivors who demonstrated impaired arm movement (NIHSS > 1)
at a level-one trauma hospital. Patients were excluded if they were on
comfort care, but otherwise we had broad inclusion as our main goal was
evaluating deployment of the technology and observing muscle activity of
all stroke survivors. We recruited patients from the acute stroke unit,
where some patients may have received initial care in the intensive
care unit. At this hospital, most stroke survivors stay in acute care
for <2 weeks, receiving daily evaluations and therapy, before being
discharged to inpatient rehabilitation, a skilled nursing facility, or
their home. Our primary objective was to evaluate whether muscle
activity could be detected during acute stroke care. We were especially
interested in determining whether EMG sensors could detect muscle
activity for those patients classified as having dense hemiplegia or
flaccidity, who could not participate or be evaluated with other
clinical measures. For each patient, we collected up to four hours of
data. We manually identified contractions for each muscle, marking the
start and stop time and coding each contraction as during periods of
movement or rest based upon concurrent accelerometer data. Details on
the data collection, EMG processing, and analyses can be found in (29, 30) and (REF), while here we aim to share key experiences in deploying this technology.
For the patients we monitored, muscle contractions were
detected from all five muscles during a single four hour collection
period during standard care (Figure 1). This was true even for the patients who had an MMT score of zero (N = 11), indicating no voluntary movement or muscle activity detected via palpation. For the participants with an MMT >0 (N
= 10), only a single 30-min time window was required to identify
contractions in all five muscles. For the patients who were initially
flaccid, we did find moderate correlations between early contraction
characteristics and scores on the MMT at follow-up. These findings
indicate that muscle activity is present during the first week after
stroke, even among participants characterized as flaccid, and EMG can
provide quantitative metrics that may have prognostic value for
predicting future function.